Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 12/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23619296 | 0.88 | HPRT1 (0.46) | ADORA2AADORA2BADORA1HPRT1PNP | |
| SCHEMBL11243652 | 0.87 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| SCHEMBL21385661 | 0.86 | HPRT1 (0.55) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL784333 | 0.84 | ADORA2A (0.51) | ADORA2AADORA2BADORA1HPRT1PNP | |
| SCHEMBL21385659 | 0.84 | ADA (0.46) | HPRT1PNPLMNA | |
| SCHEMBL11243638 | 0.84 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| SCHEMBL21417461 | 0.81 | HPRT1 (0.50) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL21127932 | 0.81 | HPRT1 (0.47) | ADORA2AADORA2BADORA1HPRT1PNP | |
| SCHEMBL13650205 | 0.80 | HPRT1 (0.43) | HPRT1PNPLMNA | |
| SCHEMBL23228187 | 0.79 | HPRT1 (0.45) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ADORA2A 58/4885ADORA2B 93/4885ADORA1 82/4885 |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | ADORA2A 58/4885ADORA2B 93/4885ADORA1 82/4885 |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, IRF3 | ADORA2A 225/4885ADORA2B 241/4885ADORA1 247/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 900/4885ADORA2B 2261/4885ADORA1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.